Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
MONTREAL and CHARLOTTE, N.C., April 07, 2026 -- Milestone
A webcast of the presentation will be available on April 13
If you are interested in meeting with the Milestone team during the conference, please contact your Needham representative.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Investor Relations
Media Relations
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Trump administration’s Intel stake up by $28 billion as INTC makes a roaring comeback
PEPE Price Climbs as Bulls Test Key Resistance Breakout

Trump Orders Navy to Destroy Iranian Fast Boats in Strait of Hormuz
Outset Media Index Competitive Review: OMI vs Similarweb, Muck Rack, Cision, and Meltwater

